Liquidia Technologies,
Inc. announced today that it has entered into a collaboration and license
agreement with Abbott to develop PRINT® nanoparticles for the delivery of
siRNA-based therapeutics. Liquidia’s PRINT technology offers the ability
to fabricate nanoparticles of precisely defined size, shape, surface chemistry,
and composition, which offers the potential to develop safer and more effective
therapies.
“Delivery has been the most significant hurdle to realizing the broad
potential of siRNA therapeutics. We are very pleased to form a partnership with
Abbott, which we hope will enable significant progress in addressing this problem,”
said Neal Fowler, Chief Executive Officer of Liquidia. “By combining Abbott’s
research and development capabilities with Liquidia’s particle design
and delivery expertise, we hope to enable the use of siRNA for therapy and provide
more targeted, effective treatment options for cancer patients.”
Under the terms of the agreement, Liquidia will provide Abbott with certain
rights to PRINT technology for the development and commercialization of siRNA
therapeutics. Financial terms were not disclosed.